Tirzepatide
Mounjaro is a prescription medicine containing tirzepatide. It acts on two gut-hormone receptors — GIP and GLP-1 — that take part in appetite regulation and blood-sugar control. Whether it is appropriate for you is a clinical decision, made after a full assessment.
Tirzepatide is a single molecule that activates two different gut-hormone receptors. Most medicines in this family act on one receptor; acting on two is what distinguishes tirzepatide pharmacologically, and it is why clinicians consider it separately from single-receptor options.
In practice, treatment is a supervised course rather than a one-off injection. It is introduced gradually, reviewed at intervals, and adjusted or stopped depending on how you tolerate it and how you respond. It is used alongside changes to eating patterns and activity, not as a replacement for them.
The purpose of a consultation is to establish whether this medicine has a genuine place in your care. For some people it does not, and a clinician may recommend a different treatment, a non-injection approach, or further investigation first.
GIP and GLP-1 are hormones released by the gut in response to food. Both take part in signalling that influences insulin release, the rate at which the stomach empties, and the sense of having eaten enough.
By activating both receptors, tirzepatide affects these signals together rather than singly. The practical effect people most often describe is feeling satisfied sooner and staying satisfied longer, which can make an agreed eating plan easier to follow.
This is a description of the mechanism, not a prediction of your result. How strongly any individual responds varies, and a clinician will set expectations with you based on your own assessment.
Written conditionally on purpose. These are areas the treatment may support in suitable patients, depending on clinical assessment — not outcomes you should expect.
This is not a self-assessment tool and it cannot tell you whether you are eligible. Eligibility depends on your medical history, current medications and a clinical assessment.
A licensed clinician reviews your health history, current medicines, previous weight-management attempts and what you are hoping to address.
Relevant measurements and, where indicated, baseline investigations. This is where suitability is genuinely determined — not on this website.
If treatment is appropriate, the clinician explains what it involves, the realistic range of outcomes, the possible side effects and the alternatives, so you can decide.
Scheduled reviews to check tolerance and progress, adjust the plan, and stop or change course if the treatment is not working for you.
Mounjaro is a prescription-only medicine. It cannot be supplied on request, purchased through this website, or started without an assessment by a licensed prescriber.
Treatment here always begins with an assessment by a licensed healthcare professional. Nothing on this website establishes that a treatment is suitable for you, and selecting a treatment does not create a prescription.
Contraindications, drug interactions and your personal and family medical history must be reviewed by a clinician before any injection is considered. Some conditions, medicines, pregnancy and breastfeeding make certain treatments unsuitable.
Side effects vary by treatment and by person, and they are discussed with you individually before you decide. Individual responses vary, and no outcome can be promised.
This website does not provide diagnosis, emergency advice or a prescribing service. If you feel unwell or have urgent symptoms, contact a doctor or your local emergency service.
Yes. It is a prescription-only medicine, so a licensed clinician must assess your medical history, current medicines and overall suitability first. There is no route to treatment that skips that step.
Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, whereas semaglutide acts on GLP-1 alone. That is a pharmacological difference, not a ranking — which is more appropriate for you, if either is, depends entirely on your clinical assessment.
No. You are welcome to say you are interested in it, and that helps focus the consultation. The decision on whether to prescribe anything, and what, remains a clinical judgement made after assessing you.
The clinician reviews how you are tolerating and responding to treatment at scheduled follow-ups. If it is not working for you, or side effects outweigh any benefit, the plan is changed or stopped. Continuing regardless is not the intention.
No. Adding a treatment creates a consultation request only. No medicine is reserved, dispensed or paid for at that point, and no prescription is created.
Semaglutide
A prescription weight-management medicine containing semaglutide, a GLP-1 receptor agonist that influences appetite signalling. Prescribed only after a clinical assessment and used with ongoing follow-up.
Consultation required · Prescription only
Fat-Burning Injections
Injectable formulations combining compounds such as B-group vitamins and amino acids. Often called fat-burning injections, though evidence for that effect is limited — a clinician will set realistic expectations.
Consultation required
